Drugs / RALZAPASTOTUG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04772989 | Mar 2021 → Aug 2025 | cervical cancer, diffuse large B-cell lymphoma, esophageal cancer, gastric cancer +4 | Arcus Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RALZAPASTOTUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095299 ↗ |
| Known as | AB308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04772989 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095299 ↗ |
| Route | Intravenous | “Administered intravenously (IV) as specified in the treatment arm” NCT04772989 ↗ |